Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new Korean study found that atrial fibrillation patients who experienced a hemoglobin drop of 2 g/dL or more after starting oral anticoagulants had nearly double the 1-year cancer rate compared to those who didn't. The association was strongest for gastrointestinal cancers. Experts say the dip shouldn't trigger panic, but clinicians shouldn't dismiss it either — it could be an early, actionable signal.
A new study published in JACC: CardioOncology suggests that a silent drop in hemoglobin after starting oral anticoagulants (OACs) for atrial fibrillation (AF) — even without visible bleeding — may be an early warning sign of cancer. Researchers analyzed nearly 7,000 new OAC users and found that those with a hemoglobin decline of 2 g/dL or more had a 1-year cancer rate of 7.2%, compared to 4.0% in those without such a drop.
The theory: anticoagulants don't cause cancer, but they lower the body's hemostatic threshold, potentially unmasking bleeding from pre-existing, clinically silent lesions — particularly in the GI tract. Experts note this could actually be a silver lining, as cancers detected this way may be caught at an earlier, more treatable stage.
By the Numbers:
Why it matters: Clinicians may be tempted to chalk up hemoglobin dips in OAC patients to the medication itself. This study signals that an unexplained drop deserves a closer look — not as a reason for alarm, but as a prompt for thoughtful, patient-specific workup that could lead to earlier cancer detection.
